Shares of Lexicon Pharmaceuticals LXRX rose more than 5% on Tuesday after the company announced that the FDA accepted its resubmitted new drug application (NDA) seeking approval for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). A final decision is expected by Dec 20, 2024. If approved, the product will be marketed under the brand name Zynquista with a commercial launch expected in early next year. Lexicon had initially submitted an NDA in 2018 for sotagliflozin in T1D indication. However, the FDA issued a complete response letter (CRL) to the NDA in 2019 after one of its advisory committees issued a split opinion regarding its approval. Management stated that the agency considers the resubmission as a complete response to this CRL. Shares of Lexicon Pharmaceuticals have surged 45.8% year to date compared with the industry’s 2.6% decline. Zacks Investment Research Image Source: Zacks Investment Research We remind investors that sotagliflozin was approved by the FDA last year to reduce the risk of death and hospitalization in adults with either heart failure or those with type II diabetes mellitus (T2D), CKD and other cardiovascular risk factors. The drug is being marketed under the name Inpefa. An oral SGLT inhibitor, the commercial launch of Inpefa continues to progress across the country, driven by demand across the cardiology community and improving payer access. Per Lexicon, Inpefa is one of the three FDA-approved SGLT inhibitors to treat heart failure. The other two SGLT inhibitors are marketed by pharma giants AstraZeneca AZN and Eli Lilly LLY. AstraZeneca markets Farxiga (dapagliflozin), while Lilly markets Jardiance (empagliflozin). LXRX is likely to face stiff competition from both these companies. Both AstraZeneca’s Farxiga and Lilly’s Jardiance are blockbuster drugs and directly compete with each other in multiple indications, including T2D and heart failure. During first-quarter 2024, AstraZeneca generated $1.89 billion from Farxiga sales, a 45% rise from the year-ago period’s levels. Lilly added $686.5 million from Jardiance sales, up 19% year over yearfrom the year-ago period’s levels. Zacks Rank Lexicon currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN):Free Stock Analysis Report Eli Lilly and Company (LLY):Free Stock Analysis Report Lexicon Pharmaceuticals, Inc. (LXRX):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...